Literature DB >> 14693668

CD40 plays a crucial role in lipopolysaccharide-induced acute lung injury.

Naozumi Hashimoto1, Tsutomu Kawabe, Kazuyoshi Imaizumi, Toru Hara, Masakazu Okamoto, Katsuyuki Kojima, Kaoru Shimokata, Yoshinori Hasegawa.   

Abstract

Activated alveolar macrophages (AMphi) are known to constitute a critical modulator of the lung inflammatory response through the production of various mediators. However, the role of activated AMphi in acute lung injury (ALI) and acute respiratory distress syndrome is less well known. To address this issue, we examined a lipopolysaccharide (LPS)-induced lung injury model for the role of activated AMphi in vivo, focusing on activation through CD40, which is one of the most important pathways for the activation of antigen-presenting cells. Without CD40, LPS-induced ALI was significantly reduced in its histological degree of injury and recruitment of neutrophils into the lung. In addition, the release in the lung of inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1beta, macrophage inflammatory protein 2, or matrix metalloproteinase was significantly reduced in mice deficient in CD40 (CD40KO). To elucidate the mechanism of this attenuation of ALI in CD40KO mice, we studied the function of AMphi ex vivo. AMphi purified from CD40KO mice could not induce expression of inducible nitric oxide synthase (iNOS) by LPS, although iNOS in wild-type AMphi was induced by LPS independently of CD40-CD154 interaction. The loss of surface expression of CD40 was enough to interrupt the expression of iNOS in AMphi in response to LPS. Also based on the tissue nitrotyrosine staining, the reactive oxygen and nitrogen intermediates seemed to be reduced in tissue in CD40KO mice. These results indicated that activation of AMphi through CD40 might be involved not only in amplification by the interaction with CD154 but also in the development of ALI by CD40 itself, and that the functional blockade of CD40 would yield one of the targets for the treatment of LPS-induced ALI and acute respiratory distress syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14693668     DOI: 10.1165/rcmb.2003-0197OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  26 in total

1.  Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial.

Authors:  Daryl J Kor; Rahul Kashyap; Richard B Weiskopf; Gregory A Wilson; Camille M van Buskirk; Jeffrey L Winters; Michael Malinchoc; Rolf D Hubmayr; Ognjen Gajic
Journal:  Am J Respir Crit Care Med       Date:  2012-01-26       Impact factor: 21.405

Review 2.  Platelets in the pathogenesis of acute respiratory distress syndrome.

Authors:  Hemang Yadav; Daryl J Kor
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-28       Impact factor: 5.464

3.  Moderate oxygen augments lipopolysaccharide-induced lung injury in mice.

Authors:  Neil R Aggarwal; Franco R D'Alessio; Kenji Tsushima; D Clark Files; Mahendra Damarla; Venkataramana K Sidhaye; Mostafa M Fraig; Vsevolod Y Polotsky; Landon S King
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-24       Impact factor: 5.464

4.  Kinetic and distinct distribution of conventional dendritic cells in the early phase of lipopolysaccharide-induced acute lung injury.

Authors:  Jun Liu; Peng-Shu Zhang; Qing Yu; Ling Liu; Yi Yang; Hai-Bo Qiu
Journal:  Mol Biol Rep       Date:  2012-10-08       Impact factor: 2.316

5.  Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury.

Authors:  Samina Yasmin Khan; Marguerite R Kelher; Joanna M Heal; Neil Blumberg; Lynn K Boshkov; Richard Phipps; Kelly F Gettings; Nathan J McLaughlin; Christopher C Silliman
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

6.  Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury.

Authors:  P R Tuinman; M C Gerards; G Jongsma; A P Vlaar; L Boon; N P Juffermans
Journal:  Clin Exp Immunol       Date:  2011-05-23       Impact factor: 4.330

7.  CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis.

Authors:  Anna Nolan; Michael Weiden; Ann Kelly; Yoshihiko Hoshino; Satomi Hoshino; Nehal Mehta; Jeffrey A Gold
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

8.  Resolution of experimental lung injury by monocyte-derived inducible nitric oxide synthase.

Authors:  Franco R D'Alessio; Kenji Tsushima; Neil R Aggarwal; Jason R Mock; Yoshiki Eto; Brian T Garibaldi; Daniel C Files; Claudia R Avalos; Jackie V Rodriguez; Adam T Waickman; Sekhar P Reddy; David B Pearse; Venkataramana K Sidhaye; Paul M Hassoun; Michael T Crow; Landon S King
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

9.  Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Sem H Phan; Kazuyoshi Imaizumi; Masaki Matsuo; Harunori Nakashima; Tsutomu Kawabe; Kaoru Shimokata; Yoshinori Hasegawa
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-18       Impact factor: 6.914

10.  Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model.

Authors:  Takayoshi Fujibayashi; Naozumi Hashimoto; Mayumi Jijiwa; Yoshinori Hasegawa; Toshihisa Kojima; Naoki Ishiguro
Journal:  BMC Pulm Med       Date:  2009-09-16       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.